Mirko Buchholz

Mirko Buchholz has extensive experience in the pharmaceutical industry, with a focus on drug development and analytical chemistry. Mirko is currently the Managing Director (CSO) at PerioTrap Pharmaceuticals GmbH, where they lead the development of an innovative anti-infective drug for the treatment of periodontitis. Prior to this role, they worked as the Head of the "Drug Design and Analytical Chemistry" Unit at Fraunhofer IZI and as a Senior Scientist in Computational/Medicinal Chemistry at Probiodrug AG. At Probiodrug AG, they also served as the Head of Computational Chemistry and played a significant role in coordinating in-silico activities in drug development. Mirko Buchholz has also gained teaching experience as a Guest Lecturer at the University of Leipzig. Mirko started their career with an internship at Bayer HealthCare, where they were involved in the development and validation of analytical methods.

Mirko Buchholz completed their education with a Bachelor's degree in Pharmacy from The Martin Luther University of Halle-Wittenberg in 2001. Mirko then pursued a Diploma (Master's Degree) in Pharmacy from the same institution, completing it in 2002. Mirko went on to undertake a PhD program in Medicinal Chemistry at Probiodrug AG and MLU - Halle/Wittenberg, which they finished in 2007.